Dwight JD - Revance Chief Counsel

RVNCDelisted Stock  USD 3.65  0.00  0.00%   

Executive

Dwight JD is Chief Counsel of Revance
Age 49
Phone615 724 7755
Webhttps://www.revance.com

Revance Management Efficiency

The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance's management efficiency ratios could be used to measure how well Revance manages its routine affairs as well as how well it operates its assets and liabilities.
Revance currently holds 478.43 M in liabilities with Debt to Equity (D/E) ratio of 2.94, implying the company greatly relies on financing operations through barrowing. Revance has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Revance's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Kye MDVentyx Biosciences
N/A
Lindsey AllenAmylyx Pharmaceuticals
N/A
Keith WhiteAmylyx Pharmaceuticals
N/A
Adam TownsendApellis Pharmaceuticals
47
JD EsqTerns Pharmaceuticals
56
Delphine ImbertPliant Therapeutics
N/A
Lily HepworthImmunocore Holdings
42
Tina VenturaMadrigal Pharmaceuticals
N/A
Yun Bai89bio Inc
N/A
Jeffrey JasperTerns Pharmaceuticals
N/A
JD EsqApellis Pharmaceuticals
52
David WambekeDiaMedica Therapeutics
41
Mark DelongApellis Pharmaceuticals
47
Perrin BSNuvalent
N/A
MS MDDiaMedica Therapeutics
51
Adam JDDay One Biopharmaceuticals
58
Carole HuntsmanMadrigal Pharmaceuticals
59
Emil MDTerns Pharmaceuticals
45
Debra SieminskiTerns Pharmaceuticals
N/A
Lukas MDApellis Pharmaceuticals
53
Matthew MetivierNuvalent
N/A
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. Revance Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 495 people. Revance (RVNC) is traded on NASDAQ Exchange in USA and employs 597 people.

Management Performance

Revance Leadership Team

Elected by the shareholders, the Revance's board of directors comprises two types of representatives: Revance inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance's management team and ensure that shareholders' interests are well served. Revance's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dwight JD, Chief Counsel
Dustin Sjuts, Vice President of Strategy and Sales
Conor Gallagher, Head Aesthetics
Jeanie Herbert, Sr. Director of Investor Relations
Mark Foley, CEO Director
Erica Jordan, Chief Officer
Azita Nejad, VP Operations
Dwight Moxie, Chief Counsel
Justin Ford, VP People
Amie Krause, Chief Officer
MD MBA, Chief Officer
Jessica Serra, Head ESG
Aubrey Rankin, Consultant
Tobin Schilke, CFO and Principal Financial Officer
Taryn Conway, Vice President of Marketing

Revance Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Consideration for investing in Revance Stock

If you are still planning to invest in Revance check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance's history and understand the potential risks before investing.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
CEOs Directory
Screen CEOs from public companies around the world
Bonds Directory
Find actively traded corporate debentures issued by US companies
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities